A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-p)

A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

Study Overview

• Status: Active, not recruiting
• Conditions: Atypical Hemolytic Uremic Syndrome
• Intervention / Treatment: Drug: Crovalimab

• Study Type: Interventional
• Enrollment (Actual): 41
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Ghent, Belgium, 9000
    • Uz Gent
  • Leuven, Belgium, 3000
    • UZ Leuven Gasthuisberg
• Brazil
  • São Paulo
    • São Paulo, São Paulo, Brazil, 05403-900
      • Inst. Da Criança- Faculdade de Medicina Usp
• Canada
  • Quebec
    • Montreal, Quebec, Canada, H3T 1C5
      • CHU Sainte-Justine
• China
  • Beijing, China, 100034
    • Peking University First Hospital
  • Beijing, China, 100045
    • Beijing Children's Hospital, Capital Medical University
  • Hangzhou, China, 310051
    • The children's hospital , Zhejiang university school of medicine
• France
  • Montpellier, France, 34295
    • Hopital Arnaud de Villeneuve
  • Paris, France, 75743
    • Gh Necker Enfants Malades
• India
  • Gujarat
    • Ahmedabad, Gujarat, India, 380016
      • Institute of Kidney Diseases and Research Centre
  • Haryana
    • Gurgaon, Haryana, India, 122001
      • Medanta-The Medicity
  • National Capital Territory of Delhi
    • New Delhi, National Capital Territory of Delhi, India, 110029
      • All India Institute Of Medical Sciences (AIIMS)
• Japan
  • Aichi, Japan, 474-8710
    • Aichi Children?s Health and Medical Center
  • Chibashi, Chibaken, Japan, 266-0007
    • Chiba Children's Hospital
• Mexico
  • Zapopan, Mexico, 45116
    • Hospital de Especialidades Puerta de Hierro S.A de C.V.
• Poland
  • Gdansk, Poland, 80-294
    • Uniwersyteckie Centrum Kliniczne
  • Lodz, Poland, 93-338
    • Instytut ?Centrum Zdrowia Matki Polki
• United States
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Children's Hospital Colorado
  • Nebraska
    • Omaha, Nebraska, United States, 68198
      • University of Nebraska
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Hackensack University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 weeks to 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Body weight >= 5 kg at screening.
• Vaccination against Neisseria meningitis serotypes A, C, W, and Y; vaccination against serotype B, according to national vaccination recommendations.
• Vaccination against Haemophilus influenzae type B and Streptococcus pneumoniae, according to national vaccination recommendations.
• For patients continuing to receive other therapies concomitantly with crovalimab (e.g., immunosuppressants, corticosteroids, mammalian target of rapamycin inhibitor (mTORi), or calcineurin inhibitors): stable dose for >=28 days prior to screening and up to the first crovalimab administration.
• For female participants of childbearing potential: an agreement to remain abstinent or use contraception.
• Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
• Onset of initial TMA presentation within 28 days prior to the first dose of crovalimab (for Naive Cohort only).
• Documented treatment with either eculizumab or ravulizumab (for Switch Cohort only).
• Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
• Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP participants in the Pretreated Cohort only).
• Known C5 polymorphism (for C5 SNP participants in the Pretreated Cohort only).

Exclusion Criteria:

• TMA associated with non-aHUS related renal disease.
• Positive direct Coombs test.
• Chronic dialysis within 90 days prior to first crovalimab administration , and /or end stage renal disease
• Identified drug exposure-related TMA.
• Presence or history of a condition that could trigger TMA, such as malignancy, bone marrow or organ transplant (other than kidney transplant) or autoimmune disease.
• History of a kidney disease, other than aHUS.
• History of Neisseria meningitidis infection within 6 months of study enrollment.
• Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
• Positive HIV test.
• Active systemic bacterial, viral, or fungal infection within 14 days before first crovalimab administration.
• Presence of fever (>= 38°C) before the first crovalimab administration (If fevers are solely due to the underlying aHUS pathology, and there is no evidence or suspicion of a systemic infection, participants may enroll).
• Multi-system organ dysfunction or failure.
• Recent intravenous immunoglobulin (IVIg) treatment.
• Pregnant or breastfeeding or intending to become pregnant.
• Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
• Recent use of tranexamic acid.
• Current or previous treatment with a complement inhibitor (for Naive Cohort only).
• First initiation of plasma exchange/plasma infusions (PE/PI) should not be more than 28 days prior to first crovalimab administration (for Naive Cohort only).
• Last PE/PI completed less than 2 hours prior to first crovalimab administration (for Naive Cohort only).
• Receiving PE/PI within 8 weeks of the first crovalimab administration (Switch Cohort only).
• Normalization of serum creatinine values at baseline (<97.5th percentile for age), (for Naive Cohort only).
• Positive for active Hepatitis B and/or C infections (HBV/HCV) (for Switch Cohort and switching C5 SNP Pretreated Cohort participants who recently received C5 inhibitor treatment).
• Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
• Diagnosis of a condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect (as demonstrated by either increased total blood homocysteine levels or MMACHC gene mutation) and TMA related to Diacylglycerol kinase ε (DGKE) nephropathy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Crovalimab; Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.

Drug: Crovalimab; Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing => 40 to <100 kg) or 1500 mg IV (for participants weighing >=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing => 40 to <100 kg) or 1020 mg SC (for participants weighing >=100 kg). Enrollment of participants weighing <40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing >=20 kg to <40 kg, followed by Group 2 participants weighing >=5 kg to <20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only)	Baseline up to Week 25 (after 24 weeks on treatment)

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of Participants with Adverse Events (AEs)	Up to 8 years
Percentage of Participants with Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (including malignant renal hypertension) and Infections (including meningococcal meningitis)	Up to 8 years
Percentage of Participants with Adverse Events (AEs) leading to Study Drug Discontinuation	Up to 8 years
Percentage of Participants with Anti-Crovalimab Antibodies	Up to 8 years
Serum Concentrations of Crovalimab over time	Up to 8 years
Time to complete TMA response (cTMAr) (Naive Cohort only)	Up to 8 years
Duration of complete TMA response (cTMAr) (Naive Cohort only)	Up to 8 years
Percentage of Participants with Clinical Manifestations of Drug-Target-Drug Complex (DTDC) formation amongst participants who switched to crovalimab treatment from eculizumab/ravulizumab treatment (Switch Cohort and switching Pretreated participants)	Up to Week 25
Change from Baseline in Dialysis Status	Baseline up to Week 25 (after 24 weeks on treatment)
Change in Estimated Glomerular Filtration Rate (eGFR) (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Percentage of Participants with Change from Baseline in Chronic Kidney Disease (CKD) stage (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Observed Value in Platelet Count (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Observed Value in Lactate Dehydrogenase (LDH) (mg/dL) (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Observed Value in Hemoglobin (mg/dL) (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Change from Baseline in Platelet Count (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Change from Baseline in Lactate Dehydrogenase (LDH) (mg/dL) (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Change from Baseline in Hemoglobin (mg/dL) (Naive and Switch Cohorts)	Baseline up to Week 25 (after 24 weeks on treatment)
Percentage of Participants with Platelet Count >= LLN (Naive Cohort only)	Baseline up to Week 25 (after 24 weeks on treatment)
Percentage of Participants with Normalisation of LDH (i.e., =< Upper Limit Normal (ULN)) (Naive Cohort only)	Baseline up to Week 25 (after 24 weeks on treatment)
Percentage of Participants with >=25% decrease in Serum Creatinine (Naive Cohort only)	Baseline up to Week 25 (after 24 weeks on treatment)
Percentage of Participants with ongoing complete TMA response (cTMAr) (Naive Cohort only)	At Week 25
Percentage of Participants with maintained TMA control (mTMAc) (Switch Cohort only)	Baseline through Week 25 (after 24 weeks on treatment)
Prevalence of Anti-Crovalimab Antibodies at Baseline	Baseline
Observed value of Pharmacodynamic Markers (CH50, Free/Total C5)	Up to 8 years

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Collaborators: Chugai Pharmaceutical
• Investigators: Study Director: Clinical Trials, Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start (Actual): November 17, 2021
• Primary Completion (Actual): July 4, 2025
• Study Completion (Estimated): May 19, 2029

Study Registration Dates

• First Submitted: July 6, 2021
• First Submitted That Met QC Criteria: July 6, 2021
• First Posted (Actual): July 12, 2021

Study Record Updates

• Last Update Posted (Actual): March 27, 2026
• Last Update Submitted That Met QC Criteria: March 26, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Cytopenia; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Hematologic Diseases; Anemia, Hemolytic; Anemia; Blood Platelet Disorders; Thrombotic Microangiopathies; Thrombocytopenia; Uremia; Hemic and Lymphatic Diseases; Hemolytic-Uremic Syndrome; Atypical Hemolytic Uremic Syndrome
• Other Study ID Numbers: BO42354; 2020-002437-15 (EudraCT Number); 2023-505638-82-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No